Key result
SGLT2i reduce CV morbidity and sustain glycemic control in T2D despite counter-regulatory metabolic adaptations.
Population
Type 2 Diabetes patients
Design
Review
Authors
Loading...
Supports SGLT2i benefits in T2D despite adaptations; leaves open mechanistic and durability questions.
This review highlights the complex hormonal and metabolic adaptations, such as increased endogenous glucose production and lipolysis, induced by SGLT-2 inhibitors in patients with type 2 diabetes.
Cersósimo et al. (2018) conducted a review in Type 2 Diabetes. Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) was evaluated. Sodium-glucose cotransporter-2 inhibitors provide durable glycemic control and reduce cardiovascular morbidity in type 2 diabetes, despite inducing counter-regulatory metabolic adaptations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: